Lupin settles Myrbetriq patent spat with Astellas for $90m
Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement. In a statement, Japan's Astellas said the specific terms of the settlement were confidential; however, …